blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3564671

EP3564671 - DIAGNOSTIC TESTS AND METHODS FOR ASSESSING SAFETY, EFFICACY OR OUTCOME OF ALLERGEN-SPECIFIC IMMUNOTHERAPY (SIT) [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.08.2022
Database last updated on 13.09.2024
FormerThe patent has been granted
Status updated on  27.08.2021
FormerGrant of patent is intended
Status updated on  30.03.2021
FormerExamination is in progress
Status updated on  05.06.2020
FormerRequest for examination was made
Status updated on  08.05.2020
FormerThe application has been published
Status updated on  04.10.2019
Most recent event   Tooltip31.05.2024Lapse of the patent in a contracting state
New state(s): MK		published on 03.07.2024  [2024/27]
Applicant(s)For all designated states
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591 / US
[2021/39]
Former [2019/45]For all designated states
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591-6706 / US
Inventor(s)01 / YANCOPOULOS, George D.
1519 Baptist Church Road
Yorktown Heights, NY 10598 / US
02 / ORENGO, Jamie
17 Maple Moor Lane
Cortlandt Manor, NY 10567 / US
 [2019/45]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2019/45]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date19178233.322.08.2014
[2019/45]
Priority number, dateUS201361869214P23.08.2013         Original published format: US 201361869214 P
[2019/45]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3564671
Date:06.11.2019
Language:EN
[2019/45]
Type: B1 Patent specification 
No.:EP3564671
Date:29.09.2021
Language:EN
[2021/39]
Search report(s)(Supplementary) European search report - dispatched on:EP26.07.2019
ClassificationIPC:G01N33/50
[2019/45]
CPC:
G01N33/6854 (EP,US); A61K49/0008 (US); G01N33/502 (EP,US);
G01N33/5088 (US); G01N2800/24 (US); G01N2800/52 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/24]
Former [2019/45]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:DIAGNOSTISCHE TESTS UND VERFAHREN ZUR BEURTEILUNG DER SICHERHEIT, DER WIRKSAMKEIT ODER DES ERGEBNISSES EINER ALLERGENSPEZIFISCHEN IMMUNTHERAPIE (SIT)[2019/45]
English:DIAGNOSTIC TESTS AND METHODS FOR ASSESSING SAFETY, EFFICACY OR OUTCOME OF ALLERGEN-SPECIFIC IMMUNOTHERAPY (SIT)[2019/45]
French:TESTS DE DIAGNOSTIC ET PROCÉDÉS D'ÉVALUATION DE LA SÉCURITÉ, DE L'EFFICACITÉ OU DU RÉSULTAT D'UNE IMMUNOTHÉRAPIE SPÉCIFIQUE AUX ALLERGÈNES (SIT)[2019/45]
Examination procedure04.05.2020Amendment by applicant (claims and/or description)
04.05.2020Examination requested  [2020/24]
04.05.2020Date on which the examining division has become responsible
09.06.2020Despatch of a communication from the examining division (Time limit: M06)
09.12.2020Reply to a communication from the examining division
31.03.2021Communication of intention to grant the patent
14.07.2021Fee for grant paid
14.07.2021Fee for publishing/printing paid
14.07.2021Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP14761497.8  / EP3036543
Opposition(s)30.06.2022No opposition filed within time limit [2022/36]
Fees paidRenewal fee
04.06.2019Renewal fee patent year 03
04.06.2019Renewal fee patent year 04
04.06.2019Renewal fee patent year 05
04.06.2019Renewal fee patent year 06
19.08.2020Renewal fee patent year 07
18.08.2021Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.08.2014
AL29.09.2021
AT29.09.2021
CY29.09.2021
CZ29.09.2021
DK29.09.2021
EE29.09.2021
ES29.09.2021
FI29.09.2021
HR29.09.2021
IT29.09.2021
LT29.09.2021
LV29.09.2021
MC29.09.2021
MK29.09.2021
NL29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SE29.09.2021
SI29.09.2021
SK29.09.2021
SM29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
IS29.01.2022
PT31.01.2022
[2024/27]
Former [2024/21]HU22.08.2014
AL29.09.2021
AT29.09.2021
CY29.09.2021
CZ29.09.2021
DK29.09.2021
EE29.09.2021
ES29.09.2021
FI29.09.2021
HR29.09.2021
IT29.09.2021
LT29.09.2021
LV29.09.2021
MC29.09.2021
NL29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SE29.09.2021
SI29.09.2021
SK29.09.2021
SM29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
IS29.01.2022
PT31.01.2022
Former [2024/18]HU22.08.2014
AL29.09.2021
AT29.09.2021
CZ29.09.2021
DK29.09.2021
EE29.09.2021
ES29.09.2021
FI29.09.2021
HR29.09.2021
IT29.09.2021
LT29.09.2021
LV29.09.2021
MC29.09.2021
NL29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SE29.09.2021
SI29.09.2021
SK29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
IS29.01.2022
PT31.01.2022
Former [2023/16]AL29.09.2021
AT29.09.2021
CZ29.09.2021
DK29.09.2021
EE29.09.2021
ES29.09.2021
FI29.09.2021
HR29.09.2021
IT29.09.2021
LT29.09.2021
LV29.09.2021
MC29.09.2021
NL29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SE29.09.2021
SI29.09.2021
SK29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
IS29.01.2022
PT31.01.2022
Former [2023/10]AL29.09.2021
AT29.09.2021
CZ29.09.2021
DK29.09.2021
EE29.09.2021
ES29.09.2021
FI29.09.2021
HR29.09.2021
IT29.09.2021
LT29.09.2021
LV29.09.2021
NL29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SE29.09.2021
SI29.09.2021
SK29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
IS29.01.2022
PT31.01.2022
Former [2023/01]AL29.09.2021
AT29.09.2021
CZ29.09.2021
DK29.09.2021
EE29.09.2021
ES29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
NL29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SE29.09.2021
SI29.09.2021
SK29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
IS29.01.2022
PT31.01.2022
Former [2022/36]AL29.09.2021
AT29.09.2021
CZ29.09.2021
DK29.09.2021
EE29.09.2021
ES29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
NL29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SE29.09.2021
SK29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
IS29.01.2022
PT31.01.2022
Former [2022/29]AL29.09.2021
AT29.09.2021
CZ29.09.2021
EE29.09.2021
ES29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
NL29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SE29.09.2021
SK29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
IS29.01.2022
PT31.01.2022
Former [2022/24]AT29.09.2021
CZ29.09.2021
EE29.09.2021
ES29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
NL29.09.2021
PL29.09.2021
RO29.09.2021
RS29.09.2021
SE29.09.2021
SK29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
IS29.01.2022
PT31.01.2022
Former [2022/23]AT29.09.2021
CZ29.09.2021
EE29.09.2021
ES29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
PL29.09.2021
RS29.09.2021
SE29.09.2021
SK29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
PT31.01.2022
Former [2022/21]AT29.09.2021
FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
RS29.09.2021
SE29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
Former [2022/10]FI29.09.2021
HR29.09.2021
LT29.09.2021
LV29.09.2021
RS29.09.2021
SE29.09.2021
BG29.12.2021
NO29.12.2021
GR30.12.2021
Former [2022/09]FI29.09.2021
LT29.09.2021
RS29.09.2021
SE29.09.2021
BG29.12.2021
NO29.12.2021
Former [2022/08]FI29.09.2021
LT29.09.2021
SE29.09.2021
BG29.12.2021
NO29.12.2021
Former [2022/07]LT29.09.2021
NO29.12.2021
Documents cited:Search[A]  - P. A. WÜRTZEN ET AL, "A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation", CLINICAL & EXPERIMENTAL ALLERGY, (20080801), vol. 38, no. 8, doi:10.1111/j.1365-2222.2008.03020.x, ISSN 0954-7894, pages 1290 - 1301, XP055154245 [A] 1-6 * the whole document * * In particular: Title; Abstract; Materials and methods section; Fig. 1. *

DOI:   http://dx.doi.org/10.1111/j.1365-2222.2008.03020.x
 [A]  - CHRISTIAN MÖBS ET AL, "Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (20121101), vol. 130, no. 5, doi:10.1016/j.jaci.2012.07.056, ISSN 0091-6749, pages 1108 - 1116.e6, XP055154058 [A] 1-6 * the whole document * * In particular: Title; Abstract; Methods section (online repository at the end of the document); Fig. E3. *

DOI:   http://dx.doi.org/10.1016/j.jaci.2012.07.056
 [A]  - A. BABAKHIN ET AL, "Experimental desensitisation using a modified allergen adsorbed onto a synthetic Immunomodulator in a murine model of allergic asthma.", ALLERGY, (20070613), vol. 62, no. Suppl. 83, ISSN 0105-4538, page 252, XP055154300 [A] 1-6 * the whole document *
 [A]  - BABAKHIN ET AL, "Allergen-specific Immunotherapy Using A Highly Modified Allergen And The Immunomodulator Polyoxidonium In A Murine Model Of Allergic Asthma", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, (20070101), vol. 119, no. 1, doi:10.1016/J.JACI.2006.11.252, ISSN 0091-6749, page S59, XP005756142 [A] 1-6 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.jaci.2006.11.252
 [X]  - KATARZYNA NIESPODZIANA ET AL, "A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (20110601), vol. 127, no. 6, doi:10.1016/j.jaci.2011.02.004, ISSN 0091-6749, pages 1562 - 1570.e6, XP055014054 [X] 1-6 * the whole document * * In particular: Title; Abstract; Materials and methods section, in essence p. 1563-1564, bridging paragraph. *

DOI:   http://dx.doi.org/10.1016/j.jaci.2011.02.004
 [Y]  - TERESA E. TWAROCH ET AL, "Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (20110701), vol. 128, no. 1, doi:10.1016/j.jaci.2011.03.011, ISSN 0091-6749, pages 178 - 184.e7, XP055014321 [Y] 1-6 * the whole document * * In particular: Title; Abstract; Methods section on page 184e.1. *

DOI:   http://dx.doi.org/10.1016/j.jaci.2011.03.011
 [Y]  - GIALLONGO A ET AL, "IgE and IgG antibodies compete for antigenic determinants of Parietaria officinalis allergen", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 17, no. 8, doi:10.1016/0161-5890(80)90095-4, ISSN 0161-5890, (19800801), pages 1019 - 1024, (19800801), XP023680141 [Y] 1-6 * the whole document * * In particular: Title and abstract; Materials and methods section; Table 1; Fig. 4; p. 1022-1023, bridging paragraph. *

DOI:   http://dx.doi.org/10.1016/0161-5890(80)90095-4
by applicantUS6596541
 US2012097565
 US2013295097
    - BRADLEY et al., J. Allergy Clin. Immunol., (19910000), vol. 88, pages 661 - 74
    - HEDLIN et al., J. Allergy Clin. Immunol., (19860000), vol. 77, pages 488 - 96
    - J. Allergy Clin. Immunol., (20070000), vol. 120, pages 25 - 85
    - DUFFORT, O.A. et al., Mol. Immunol., (19910000), vol. 28, pages 301 - 309
    - KRISTENSEN, A.K. et al., Biol. Chem., (19970000), vol. 378, pages 899 - 908
    - KAISER L. et al., J. Biol. Chem., (20030000), vol. 278, no. 39, pages 37730 - 37735
    - "GenBank", Database accession no. NP _001041618.1
    - PADLAN et al., FASEB J., (19950000), vol. 9, pages 133 - 139
    - VAJDOS et al., J Mol Biol, (20020000), vol. 320, pages 415 - 428
    - TAYLOR et al., Nucl. Acids Res., (19920000), vol. 20, pages 6287 - 6295
    - SHAMJI et al., J. Immunol. Methods, (20060000), vol. 317, no. 1-2, pages 71 - 79
    - POWELL et al., "Compendium of excipients for parenteral formulations", J Pharm Sci Technol, (19980000), vol. 52, pages 238 - 311, XP009119027
    - WU et al., J. Biol. Chem., (19870000), vol. 262, pages 4429 - 4432
    - GOODSON, Medical Applications of Controlled Release, (19840000), vol. 2, pages 115 - 138
    - LANGER, Science, (19900000), vol. 249, pages 1527 - 1533
    - BRADLEY et al., J Allergy Clin Immunol, (19910000), vol. 88, pages 661 - 74
    - CHAPMAN MD et al., J. Immunol., (19880000), vol. 140, pages 812 - 818
    - KULIS et al., J. Allergy Clin Immunol., (20110000), vol. 127, no. 1, pages 81 - 88
    - EVAN GI et al., "Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product", Mol. Cell. Biol., (19850000), vol. 5, pages 3610 - 3616, XP000856291
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.